HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vasoactive Intestinal Peptide Ameliorates Acute Myocarditis and Atherosclerosis by Regulating Inflammatory and Autoimmune Responses.

Abstract
Vasoactive intestinal peptide (VIP) is a neuropeptide that exerts various vascular and cardioprotective functions and regulates immune function and inflammatory response at multiple levels. However, its role in inflammatory cardiovascular disorders is largely unknown. Myocarditis and atherosclerosis are two inflammatory and autoimmune cardiovascular diseases that cause important adverse circulatory events. In this study, we investigate the therapeutic effects of VIP in various well-established preclinical models of experimental autoimmune myocarditis and atherosclerosis. Intraperitoneal injection of VIP during the effector phase of experimental autoimmune myocarditis in susceptible BALB/c mice significantly reduced its prevalence, ameliorated signs of heart hypertrophy and injury, attenuated myocardial inflammatory infiltration, and avoided subsequent profibrotic cardiac remodeling. This effect was accompanied by a reduction of Th17-driven cardiomyogenic responses in peripheral lymphoid organs and in the levels of myocardial autoantibodies. In contrast, acute and chronic atherosclerosis was induced in apolipoprotein E-deficient mice fed a hyperlipidemic diet and subjected to partial carotid ligation. Systemic VIP treatment reduced the number and size of atherosclerotic plaques in carotid, aorta, and sinus in hypercholesterolemic mice. VIP reduced Th1-driven inflammatory responses and increased regulatory T cells in atherosclerotic arteries and their draining lymph nodes. VIP also regulated cholesterol efflux in macrophages and reduced the formation of foam cells and their presence in atherosclerotic plaques. Finally, VIP inhibited proliferation and migration of smooth muscle cells and neointima formation in a mouse model of complete carotid ligation. These findings encourage further studies aimed to assess whether VIP can be used as a pharmaceutical agent to treat heart inflammation and atherosclerosis.
AuthorsRaquel Benitez, Virginia Delgado-Maroto, Marta Caro, Irene Forte-Lago, Mario Duran-Prado, Francisco O'Valle, Andrew H Lichtman, Elena Gonzalez-Rey, Mario Delgado
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 200 Issue 11 Pg. 3697-3710 (06 01 2018) ISSN: 1550-6606 [Electronic] United States
PMID29669783 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2018 by The American Association of Immunologists, Inc.
Chemical References
  • Apolipoproteins E
  • Autoantibodies
  • Neuropeptides
  • Vasoactive Intestinal Peptide
Topics
  • Animals
  • Apolipoproteins E (immunology)
  • Atherosclerosis (immunology)
  • Autoantibodies (immunology)
  • Autoimmune Diseases (immunology)
  • Autoimmunity (immunology)
  • Disease Models, Animal
  • Female
  • Inflammation (immunology)
  • Lymph Nodes (immunology)
  • Macrophages (immunology)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Muscle, Smooth (immunology)
  • Myocarditis (immunology)
  • Myocardium (immunology)
  • Neuropeptides (immunology)
  • T-Lymphocytes, Regulatory (immunology)
  • Th17 Cells (immunology)
  • Vasoactive Intestinal Peptide (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: